Azathioprine in the management of enteropathy in cystic fibrosis.
作者信息
Tan Hui-Leng, Shah Neil, Suri Ranjan
机构信息
Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
出版信息
J R Soc Med. 2011 Jul;104 Suppl 1(Suppl 1):S40-3. doi: 10.1258/jrsm.2011.s11107.
Abstract
摘要
相似文献
1
Azathioprine in the management of enteropathy in cystic fibrosis.
J R Soc Med. 2011 Jul;104 Suppl 1(Suppl 1):S40-3. doi: 10.1258/jrsm.2011.s11107.
2
[Therapy of digestive insufficiency in cystic fibrosis].
Pediatria (Napoli). 1981 Sep 30;89(3):305-14.
3
Gastrointestinal manifestations of cystic fibrosis.
Clin Pediatr (Phila). 1999 Dec;38(12):735-8. doi: 10.1177/000992289903801207.
4
Surgical gastrointestinal disease in patients with cystic fibrosis of the pancreas.
N C Med J. 1971 May;32(5):169-84.
5
The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients.
Pediatr Pulmonol. 2013 Dec;48(12):1181-9. doi: 10.1002/ppul.22697. Epub 2013 Jul 4.
6
Gastrointestinal complications in cystic fibrosis.
J R Soc Med. 1992;85 Suppl 19(Suppl 19):13-9.
7
Gastrointestinal manifestations of cystic fibrosis.
Pediatr Ann. 1997 Apr;26(4):235-41. doi: 10.3928/0090-4481-19970401-06.
8
Cystic fibrosis and the gastrointestinal tract.
J Pediatr Health Care. 1996 Mar-Apr;10(2):51-7. doi: 10.1016/S0891-5245(96)90027-9.
9
The late gastrointestinal manifestations of cystic fibrosis of the pancreas.
Radiology. 1973 Feb;106(2):377-81. doi: 10.1148/106.2.377.
10
Changing patterns of gastrointestinal manifestations of cystic fibrosis. Survey of recent progress in diagnosis and treatment.
Clin Pediatr (Phila). 1970 Oct;9(10):588-93. doi: 10.1177/000992287000901008.
本文引用的文献
1
Evidence of intestinal inflammation in patients with cystic fibrosis.
J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8. doi: 10.1097/MPG.0b013e3181d1b013.
2
Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract.
Am J Physiol Gastrointest Liver Physiol. 2009 Nov;297(5):G861-8. doi: 10.1152/ajpgi.00145.2009.
3
Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 2010 Feb;50 Suppl 1:S14-34. doi: 10.1097/MPG.0b013e3181c92caa.
4
Lymphocytic leiomyositis and myenteric ganglionitis are intrinsic features of cystic fibrosis: studies in distal intestinal obstruction syndrome and meconium ileus.
J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):42-51. doi: 10.1097/MPG.0b013e318186d35a.
5
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
Inflamm Bowel Dis. 2008 Jul;14(7):949-54. doi: 10.1002/ibd.20412.
6
Intestinal dysmotility in inflammatory bowel disease: mechanisms of the reduced activity of smooth muscle contraction.
Inflammopharmacology. 2005;13(1-3):103-11. doi: 10.1163/156856005774423773.
7
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. doi: 10.1111/j.1440-1746.2005.03832.x.
8
Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration.
Aliment Pharmacol Ther. 2004 Oct 1;20(7):813-9. doi: 10.1111/j.1365-2036.2004.02174.x.
9
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Gastroenterol Clin North Am. 2004 Jun;33(2):209-34, viii. doi: 10.1016/j.gtc.2004.02.004.
10
Inflammation of the cystic fibrosis mouse small intestine.
Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G1032-41. doi: 10.1152/ajpgi.00473.2003. Epub 2004 Jan 22.
Zotero 插件